Prescient Therapeutics Ltd

ASX:PTX ISIN:AU000000PTX3

Prescient Therapeutics Limited is a clinical-stage oncology company. The Company's principal activities include in-licensing of intellectual property; the preparation for and conduct of clinical trials relating to the Company's products; business development associated with the promotion of its technologies and products, and business development associated with developing collaborative, partnership relationships and corporate transactions. 
 
           

Voir en d'autres langues

Nouvelles

###

138,456 COMPANY PROFILE VIEWS

  • This Page Viewed: (7 derniers jours: 27) (Last 30 Days: 74) (Since Published: 10597) 

Company Data

    Fax
  • (03) 9853 5134 
  • Principal Sector
  • Health & Pharm 
  • Principal Industry
  • Biotechnology 
  • Homepage
  • www.virax.com.au/

More News Results

  • 2025/04/17: Prescient Therapeutics - Investor Briefing*
  • 2025/04/16: PTX-100 receives U.S. FDA Fast Track Designation*
  • 2025/04/11: Initial Director's Interest Notice*
  • 2025/04/10: PTX appoints Melanie Farris as Non-Executive Director*
  • 2025/04/01: Final Director's Interest Notice*
  • 2025/03/31: Prescient Therapeutics - Investor Briefing*
  • 2025/03/26: PTX Opens First Clinical site for PTX-100 Phase 2a Study*
  • 2025/03/24: Change of Chief Medical Officer*
  • 2025/03/21: PTX-100 clinical data presented at leading TCL meeting*
  • 2025/03/17: Change of Director's Interest Notice*
*refer to company website